Teva Pharmaceuticals reported on Monday the availability of the first available prescription generic THIOLA (tiopronin) tablets for the prevention of kidney stones in the US.
In combination with high fluid intake, alkali and diet modification, the generic THIOLA (tiopronin) tablets are indicated for the prevention of cystine (kidney) stone formation in adults and paediatric patients nine years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.
With nearly 550 generic medicines available, the company has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the US.
In addition, Teva Pharmaceuticals is the US affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA), a specialist in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US